16 Feb 2021 09:25
Â
Ap19
FORM 8.3 - Amendment to Sales
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) | Barclays PLC. | |
Company dealt in | WILLIS TOWERS WATSON PLC | |
Class of relevant security to which the | ORD | |
dealings being disclosed relate (Note 2) | ||
Date of dealing | 11 February 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
Class of relevant security: | ORD | ||||
Long | Short | ||||
Number | (%) | Number | (%) | ||
(1) | Relevant securities | Â | Â | Â | Â |
2,159,121 | 1.67% | 609,585 | 0.47% | ||
 |  |  |  | ||
(2) | Derivatives (other than options): | Â | Â | Â | Â |
273,127 | 0.21% | 358,405 | 0.28% | ||
 |  |  |  | ||
(3) | Options and agreements to | Â | Â | Â | Â |
purchase/sell: | 6,000 | 0.00% | 6,000 | 0.00% | |
 |  |  |  | ||
TOTAL: | Â | Â | Â | Â | |
2,438,248 | 1.89% | 973,990 | 0.76% | ||
 |  |  |  |
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Class of relevant security: | Long | Short | ||||
 | Number |  | (%) | Number |  | (%) |
(1) Relevant securities | Â | Â | ||||
 (2) Derivatives (other than options) |  |  | ||||
 (3) Options and agreements to purchase/sell |  |  | ||||
Total | Â | Â | ||||
 |
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale | Number of relevant securities | Price per unit |
Purchase | 1 | 230.2800 USD |
Purchase | 1 | 228.6700 USD |
Purchase | 1 | 228.5900 USD |
Purchase | 2 | 228.5000 USD |
Purchase | 10 | 228.4500 USD |
Purchase | 100 | 228.1950 USD |
Purchase | 100 | 228.1800 USD |
Purchase | 100 | 227.6100 USD |
Purchase | 100 | 227.6132 USD |
Purchase | 236 | 230.7902 USD |
Purchase | 308 | 228.5036 USD |
Purchase | 581 | 229.8763 USD |
Purchase | 777 | 228.2741 USD |
Purchase | 1,231 | 229.7845 USD |
Purchase | 2,100 | 229.1960 USD |
Purchase | 2,990 | 228.9086 USD |
Purchase | 3,459 | 228.7460 USD |
Purchase | 5,773 | 231.0540 USD |
Purchase | 6,194 | 228.5688 USD |
Purchase | 7,500 | 229.1655 USD |
Purchase | 14,769 | 228.8388 USD |
Purchase | 16,642 | 228.4800 USD |
Purchase | 48,445 | 228.3512 USD |
Sale | 1 | 228.4700 USD |
Sale | 2 | 230.3750 USD |
Sale | 9 | 228.4744 USD |
Sale | 10 | 228.2480 USD |
Sale | 12 | 231.8800 USD |
Sale | 19 | 228.3750 USD |
Sale | 53 | 228.8200 USD |
Sale | 87 | 228.2700 USD |
Sale | 100 | 227.8600 USD |
Sale | 200 | 231.1600 USD |
Sale | 226 | 231.7300 USD |
Sale | 300 | 230.4300 USD |
Sale | 338 | 228.5473 USD |
Sale | 386 | 229.6576 USD |
Sale | 422 | 229.4138 USD |
Sale | 475 | 228.5452 USD |
Sale | 539 | 228.2289 USD |
Sale | 594 | 228.8353 USD |
Sale | 600 | 230.1366 USD |
Sale | 740 | 228.3200 USD |
Sale | 803 | 228.8104 USD |
Sale | 816 | 228.4801 USD |
Sale | 846 | 228.8546 USD |
Sale | 876 | 228.8629 USD |
Sale | 891 | 228.8807 USD |
Sale | 913 | 228.0211 USD |
Sale | 920 | 228.1422 USD |
Sale | 1,041 | 228.6731 USD |
Sale | 1,072 | 228.3721 USD |
Sale | 1,155 | 228.2965 USD |
Sale | 1,525 | 229.8486 USD |
Sale | 1,588 | 228.8185 USD |
Sale | 1,692 | 229.0428 USD |
Sale | 1,712 | 228.7430 USD |
Sale | 2,188 | 228.7828 USD |
Sale | 2,265 | 228.3543 USD |
Sale | 3,090 | 228.8667 USD |
Sale | 3,217 | 229.2497 USD |
Sale | 3,489 | 228.6783 USD |
Sale | 4,059 | 231.5789 USD |
Sale | 5,336 | 228.3639 USD |
Sale | 5,392 | 228.4800 USD |
Sale | 12,309 | 228.4938 USD |
Sale | 16,390 | 228.8184 USD |
Sale | 32,742 | 228.3378 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (Note 5) |
 |  |  |  |
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
 |  |  |  |  |  |  |
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
 |  |  |
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
 |  |   |
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 (Open Positions) attached? | YES |
Date of disclosure: | 16 Feb 2021 |
Contact name: | Large Holdings Regulatory Operations |
Telephone number: | 020 3134 7213 |
If a connected EFM, name of offeree/offeror with which connected | |
If a connected EFM, state nature of connection |
Ap23
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)
OPEN POSITIONS (Note 1)
Product name | Written or | Number of | Exercise | Type | Expiry |
 | purchased | relevant securities | price |  | date |
 |  | to which the option |  |  |  |
 |  | or derivative |  |  |  |
 |  | relates |  |  |  |
Call Options | Purchased | 6,000 | 220.0000 | American | Jul 16, 2021 |
Put Options | Purchased | -6,000 | 200.0000 | American | Jul 16, 2021 |
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005558/en/
Copyright Business Wire 2021